A therapeutic composition for treatment of cancer in a mammal is disclosed. The composition comprises an effective amount of a yeast beta-glucan composition which is suitable for oral administration and for absorption through the gastrointestinal tract of the mammal. The above therapeutic compositio
A therapeutic composition for treatment of cancer in a mammal is disclosed. The composition comprises an effective amount of a yeast beta-glucan composition which is suitable for oral administration and for absorption through the gastrointestinal tract of the mammal. The above therapeutic composition may further comprise antitumor antibodies or cancer vaccine composition, wherein the antitumor activities of the antitumor antibodies or the cancer vaccine composition are enhanced by the yeast glucan.
대표청구항▼
1. A method of treating cancer in a subject, comprising administering to the subject: (a) an antitumor antibody that binds to cancer cells expressing an antigen selected from the group consisting of CD20, CD22, CD25, HER2, EGFR, GD2, and GD3; and(b) a composition comprising an effective amount of a
1. A method of treating cancer in a subject, comprising administering to the subject: (a) an antitumor antibody that binds to cancer cells expressing an antigen selected from the group consisting of CD20, CD22, CD25, HER2, EGFR, GD2, and GD3; and(b) a composition comprising an effective amount of a β-glucan, wherein the β-glucan enhances the anti-tumor activity of said antibody, wherein the β-glucan comprises a β-1,3 backbone and at least one β-1,3 side chain of two or more glucose units linked to the backbone by β-1,6 glycosidic bonds, and wherein the β-glucan has a molecular weight from about 6 kDa to about 30 kDa. 2. The method of claim 1, wherein the β-glucan is isolated from yeast. 3. The method of claim 1, wherein the β-glucan is isolated from Saccharomyces Cerevisiae. 4. The method of claim 1, wherein the β-glucan is a particulate or soluble glucan, capable of inducing cytokines. 5. The method of claim 1, wherein the antibody is a monoclonal antibody or complement-activating antibody. 6. The method of claim 1, wherein the antibody is capable of activating an antibody dependent cell-mediated cytotoxicity. 7. The method of claim 1, wherein the β-glucan is administered orally or intravenously. 8. A method of treating cancer in a subject, comprising administering to the subject: (a) an antitumor antibody that binds to cancer cells of neuroblastoma, melanoma, non-Hodgkin's lymphoma, breast cancer, Epstein-Barr related lymphoma, Hodgkin's lymphoma, and epidermoid carcinoma; and(b) a composition comprising an effective amount of a β-glucan, wherein the β-glucan enhances the anti-tumor activity of said antibody, wherein the β-glucan comprises a β-1,3 backbone and at least one β-1,3 side chain of two or more glucose units linked to the backbone by β-1,6 glycosidic bonds, and wherein the β-glucan has a molecular weight from about 6 kDa to about 30 kDa. 9. The method of claim 8 wherein the β-glucan is isolated from yeast. 10. The method of claim 8, wherein the β-glucan is isolated from Saccharomyces Cerevisiae. 11. The method of claim 8, wherein the β-glucan is a particulate or soluble glucan, capable of inducing cytokines. 12. The method of claim 8, wherein the antibody is a monoclonal antibody or complement-activating antibody. 13. The method of claim 8, wherein the antibody is capable of activating an antibody dependent cell-mediated cytotoxicity. 14. The method of claim 8, wherein the β-glucan is administered orally or intravenously.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (53)
Kozbor,Danuta; Kaneko,Yutaro, β-glucans encapsulated in liposomes.
Nikl Libor H. (Port Coquitlam CAX) Allbright Lawrence J. (Burnaby CAX), Composition and method to enhance the efficacy of a fish vaccine and to stimulate the immune system of fish.
Jamas Spiros ; Easson ; Jr. D. Davidson ; Ostroff Gary R., Enhancement of non-specific immune defenses by administration of underivatized, aqueous soluble glucans.
Bondeson Anders (Gothenburg SEX) Isaak Bernhard (Lausanne CHX) Perrenoud Andre (Nyon CHX) Tran Minh Q. (Lausanne CHX), High-performance gyrotron for production of electromagnetic millimeter or submillimeter waves.
Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is a.
Cheever, Martin A.; Disis, Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated.
Lane H. Clifford (Bethesda MD) Kovacs Joseph A. (Potomac MD) Fauci Anthony S. (Washington DC), Immunologic enhancement with intermittent interleukin-2 therapy.
Jamas Spiros (Boston MA) Easson ; Jr. D. Davidson (Shrewsbury MA) Ostroff Gary R. (Worcester MA), Method for immune system activation by administration of a b
상세보기
Jamas Spiros ; Easson ; Jr. D. Davidson ; Ostroff Gary R., Method for producing soluble glucans.
Williams David L. (River Ridge LA) Browder I. William (New Orleans LA) DiLuzio ; deceased Nicholas R. (late of Gretna LA by Nicholas M. DiLuzio ; legal representative), Methods and compositions for prophylactic and therapeutic treatment of infections.
Williams David L. (River Ridge LA) Browder I. William (New Orleans LA) Diluzio ; deceased Nicholas R. (late of Gretna LA by Nicholas M. Diluzio ; legal representative), Methods and compositions for prophylactic and therapeutic treatment of infections.
Brandt Michael (Iffeldorf DEX) Endl Josef (Weilheim DEX) Jungfer Herbert (Starnberg DEX) Albert Winfried (Eberfing DEX), Monoclonal antibodies against melanoma.
Schlessinger Joseph ; Givol David,ILX ; Bellot Francoise,FRX ; Kris Richard ; Ricca George A. ; Cheadle Christopher ; South Victoria J., Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same.
Chatterjee Malaya ; Foon Kenneth A. ; Chatterjee Sunil K., Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma.
Robbins Ernest A. (High Ridge MO) Seeley Robert D. (Crestwood MO), Process for the prevention and reduction of elevated blood cholesterol and triglycerides levels.
Williams David L. (River Ridge LA) Browder I. William (New Orleans LA) DiLuzio ; deceased Nicholas R. (late of New Orleans LA by Nicholas M. DiLuzio ; legal representative), Soluble phosphorylated glucan: methods and compositions for treatment of neoplastic diseases.
Donzis Byron A. (#18 W. Rivercrest Houston TX 77042), Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional u.
Donzis Byron A. (#18 W. Rivercrest Houston TX 77042), Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional u.
Anderson Darrell R. ; Hanna Nabil ; Leonard John E. ; Newman Roland A. ; Reff Mitchell E. ; Rastetter William H., Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen.
Jamas Spiros (Boston MA) Easson ; Jr. D. Davidson (Shrewsbury MA) Ostroff Gary R. (Worcester MA), Use of aqueous soluble glucan preparations to stimulate platelet production.
Jamas Spiros ; Easson ; Jr. D. Davidson ; Ostroff Gary R., Uses for underivatized, aqueous soluble .beta.(1-3) glucan and compositions comprising same.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.